English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Bladder cancer (BC) is emerged as a highly prevalent malignancy associated with high morbidity and mortality and its incidence has increased over the last decades (1,2). At present, various therapies including surgery, chemotherapy and radiation treatment have been widely applied in the therapy of BC (1). However, the advances in BC treatment have been greatly restricted in the past decades due to the lack of understanding of its pathogenic mechanism. Thus, it is urgent to elaborate the pathogenic mechanism of BC. Recently, long noncoding RNAs (lncRNAs) have emerged as the Original Article

Long non-coding RNA MEG3 functions as a competing endogenous RNA of miR-93 to regulate bladder cancer progression via PI3K/AKT/mTOR pathway